<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752555</url>
  </required_header>
  <id_info>
    <org_study_id>00287597</org_study_id>
    <nct_id>NCT02752555</nct_id>
  </id_info>
  <brief_title>Severe Male Factor Infertility Management</brief_title>
  <acronym>OAT</acronym>
  <official_title>Investigating the Effect of Modifiable Lifestyle Factors in Severe Oligoasthenotertozoospermic Men Combined With Antioxidant Treatment Prior ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first to evaluate the effect of oral supplementation with antioxidants
      combined with lifestyle modification for severe male factor partner of couples undergoing
      ICSI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients underwent a therapy of a three-month period of treatment with either oral
      L-carnitine only (2g daily) or oral carnitine (2g daily) combined with modifiable lifestyle
      factors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Oligoasthenoteratozoospermia</condition>
  <arm_group>
    <arm_group_label>Antioxidant group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidant+modifiable lifestyle factors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antioxidant (l-cratinine) + modifiable lifestyle factors</intervention_name>
    <description>All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.</description>
    <arm_group_label>Antioxidant+modifiable lifestyle factors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Long protocol for ovulation

          -  Oligoasthenoteratozoospermic male partner ( (count &lt; 0.5 million/ml, Motility=&lt; 40%
             Progressive motility =&lt;10 %, Abnormal forms &gt;99%).

          -  Fresh semen samples.

        Exclusion Criteria:

          -  Day 3 embryo transfer

          -  Incomplete ICSI cycles

          -  Endometrial thickness&gt; 7mm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah Elbashir</last_name>
    <role>Study Director</role>
    <affiliation>Department of Urology, Benha university, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salah Elbashir, M.Sc</last_name>
    <phone>+201221371738</phone>
    <email>Dr.salah.elbashir@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasmin Magdi, M.Sc</last_name>
    <phone>+201282313979</phone>
    <email>Yas.magdi@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dar Almaraa fertility and gynacology center</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Magdi, M.Sc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elite fertility care center</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Ayman Rashed, pHD</last_name>
      <phone>+201006023284</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nile badrawi Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed El-Damen, M.Sc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Tremellen K, Miari G, Froiland D, Thompson J. A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Aust N Z J Obstet Gynaecol. 2007 Jun;47(3):216-21.</citation>
    <PMID>17550489</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>November 25, 2016</last_update_submitted>
  <last_update_submitted_qc>November 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Salah Elbashir</investigator_full_name>
    <investigator_title>Assisting lecturer of Urology</investigator_title>
  </responsible_party>
  <keyword>Oligoasthenoteratozoospermia</keyword>
  <keyword>Male factor managment</keyword>
  <keyword>Intacytoplasmic sperm injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligospermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publishing a manuscript</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

